EHA 2023 | BMS-986393: GPRC5D-targeted CAR for R/R myeloma
Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, discusses the results from a recent Phase I study investigating the use of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory (R/R) multiple myeloma. The overall response rate was 89% (17/19) in efficacy-evaluable patients, including responses in 7/9 pts treated with prior BCMA-directed therapies, including CAR T cells. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So BMS-986393 is a first in-human novel anti-GPRC5D-directed CAR-T cell therapy. We were able to share the updated results from the Phase I study here today. It is a second-generation autologous CAR-T cell therapy. And what we saw today was that the safety profile was very manageable – most of the toxicities were, hematologic predominantly, the grade three and four toxicities were mostly hematologic...
So BMS-986393 is a first in-human novel anti-GPRC5D-directed CAR-T cell therapy. We were able to share the updated results from the Phase I study here today. It is a second-generation autologous CAR-T cell therapy. And what we saw today was that the safety profile was very manageable – most of the toxicities were, hematologic predominantly, the grade three and four toxicities were mostly hematologic. And that’s consistent with the profile of chimeric antigen receptor therapy and relapsed myeloma. The efficacy of this agent was very attractive, had high response rates of 86.5% with complete response rates of 38.5%. And this is really exciting news for our patients with multiple myeloma as we expand, sort of, immunotherapeutic and other avenues for treatment, particularly in those who have already received B-cell maturation antigen therapies.
Read more...
